An Exciting New Treatment Option
Please check this section frequently for updates on news announcements, industry events, and for our latest media resources.
Leading organizations and Members of Parliament come together at a special event sponsored by Oraya Therapeutics. More >
AMD Alliance International leads an event at the House of Commons addressing current issues with diagnosing, treating and managing the growing number of aging people affected by age-related macular degeneration (AMD), the leading cause of blindness in the western world.
Latest Press Releases
Tuesday, March 3, 2015 | Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung. This new indication of use expands upon Oraya’s prior approval for the treatment of wet Age Related Macular Degeneration (AMD) and may offer patients in the United Kingdom, Germany and Switzerland a new treatment option for a vision-threatening condition. More >
Thursday, January 22, 2015 | The AMD Alliance International today led an event at the House of Commons that addressed the current issues the NHS is facing with diagnosing, treating and managing the growing number of ageing people affected by age – related macular degeneration (AMD), the leading cause of blindness in the western world. The event was hosted by Sir David Amess, Member of Parliament for Southend West and sponsored by Oraya Therapeutics, Inc. More >
Wednesday, January 7, 2015 | Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. (Oraya) jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years…More >
Saturday, September 13, 2014 | Oraya Therapeutics Inc. announced today that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. Oraya Therapy uses low-energy, highly targeted X-rays to treat Wet AMD and is intended as a one-time procedure with the potential to maintain vision while reducing the required number of anti-VEGF injections into the eye. More >
Wednesday, August 20, 2014 | Sheffield Teaching Hospitals NHS Foundation Trust has become the first NHS hospital in the UK to start offering appropriate patients a new non-invasive treatment for wet age-related macular degeneration (wet AMD)…More >
Tuesday, August 5, 2014 | Oraya® Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD)…More >
Tuesday, July 22, 2014 | Oraya® Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany…More >
January 23, 2015 | Eyewire Today
The UK’s Leading Blindness Organizations Come Together at House of Commons to Call for Better Funding, Screening, and Treatment for Macular Degeneration.
October 6, 2014 | Mail Online: Health
Painless X-ray that can save failing eyes in 15 minutes.
October 1, 2014 | Fierce Medical Devices
Oraya Therapetics Named Among Fierce Medical Devices 2014 Fierce 15.
September 21, 2014 | Retinal Physician eUpdate
INTREPID Study of Oraya Therapy Continues to Show Favorable Safety Profile.
September 14, 2014 | Eyewire Today
Three-Year Data from Oraya Therapeutics’ INTREPID Study Continue to Show Favorable Safety Profile of Non-Invasive Wet AMD Therapy.
May 29, 2014 | San Francisco Business Times
Oraya Therapeutics named to San Francisco Business Times I-List — the 40-most innovative life science companies in the Bay Area.